Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

International Journal of Cancer

Volumn 92, Issue 3, 2001, Pages 361-369

  Luo, Jianying ^a   Guo, Ping ^a   Matsuda, Kei ^b   Truong, Nhan ^b   Lee, Annie ^a   Chun, Carlene ^b   Cheng, Shi Yuan ^a   Korc, Murray ^b  

^a University of Irvine   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogensis; Anti sense RNA; Pancreatic cancer; Tumorigenicity; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CULTURE MEDIUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CARCINOGENICITY TESTS; CELL DIVISION; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; RNA; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035342593     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1202     Document Type: Article

References (61)

1. Molecular and biological properties of vascular endothelial growth factor
2. VPF/VEGF and the angiogenic response
3. Signal relays in the VEGF system
4. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
5. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
6. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
7. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
8. Cloning and characterization of a novel human gene related to vascular endothelial growth factor
9. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
10. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D
11. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
12. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
13. Regulation of angiogenesis via vascular endothelial growth factor receptors
14. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular thelium
15. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
16. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
17. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
18. Molecular and biological properties of the vascular endothelial growth factor family of proteins
19. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
20. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
21. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
22. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
23. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
24. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
25. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
26. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/ KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
27. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
28. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression
29. Cancer statistics 1989
30. Pancreatic carcinoma
31. Molecular versus conventional markers in pancreatic cancer
32. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma
33. Prognostic significance of angiogenesis in human pancreatic cancer
34. A simplified method for growth of human microvascular endothelial cells results in decreased senescence and continued responsiveness to cytokines and growth factors
35. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
36. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum
37. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
38. Modification of the acid guanidinium thiocyanate-phenol-chloroform method for nuclear RNA isolation
39. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
40. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
41. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo
42. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
43. JC70: A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections
44. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis
45. What is the evidence that tumors are angiogenesis dependent?
46. Angiogenesis in cancer, vascular, rheumatoid and other disease
47. Secretion of vascular endothelial growth factor in ovarian cancer
48. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
49. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
50. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
51. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions
52. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer
53. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
54. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
55. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
56. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
57. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
58. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
59. Viral vectors for gene transfer: A review of their use in the treatment of human diseases
60. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain